About: Ebola Virus Entry: From Molecular Characterization to Drug Discovery

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ebola Virus Entry: From Molecular Characterization to Drug Discovery Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Ebola Virus Entry: From Molecular Characterization to Drug Discovery
Creator	Calistri, Arianna Palù, Giorgio Parolin, Cristina Salata, Cristiano Alvisi, Gualtiero Celestino, Michele
Source	PMC
abstract	Ebola Virus Disease (EVD) is one of the most lethal transmissible infections, characterized by a high fatality rate, and caused by a member of the Filoviridae family. The recent large outbreak of EVD in Western Africa (2013–2016) highlighted the worldwide threat represented by the disease and its impact on global public health and the economy. The development of highly needed anti-Ebola virus antivirals has been so far hampered by the shortage of tools to study their life cycle in vitro, allowing to screen for potential active compounds outside a biosafety level-4 (BSL-4) containment. Importantly, the development of surrogate models to study Ebola virus entry in a BSL-2 setting, such as viral pseudotypes and Ebola virus-like particles, tremendously boosted both our knowledge of the viral life cycle and the identification of promising antiviral compounds interfering with viral entry. In this context, the combination of such surrogate systems with large-scale small molecule compounds and haploid genetic screenings, as well as rational drug design and drug repurposing approaches will prove priceless in our quest for the development of a treatment for EVD.
has issue date	2019-03-19(xsd:dateTime)
bibo:doi	10.3390/v11030274
bibo:pmid	30893774
has license	cc-by
sha1sum (hex)	1c7d1097a0fc23516fc084e127333ec4bbf9ca94
schema:url	https://doi.org/10.3390/v11030274
resource representing a document's title	Ebola Virus Entry: From Molecular Characterization to Drug Discovery
has PubMed Central identifier	PMC6466262
has PubMed identifier	30893774
schema:publication	Viruses
resource representing a document's body	covid:1c7d1097a0fc23516fc084e127333ec4bbf9ca94#body_text
is schema:about of	named entity 'VIRAL LIFE CYCLE' named entity 'STUDY' named entity 'APPROACHES' named entity 'RATE' named entity 'BIOSAFETY LEVEL' named entity 'FAR' named entity 'SYSTEMS' named entity 'NEEDED' named entity 'HAPLOID' named entity 'ECONOMY' named entity 'CAUSED BY' named entity 'RATIONAL DRUG DESIGN' named entity 'SMALL MOLECULE' named entity 'HIGH' named entity 'WORLDWIDE' named entity 'VIRUS ENTRY' named entity 'IN VITRO' named entity 'EBOLA VIRUS' named entity 'MOLECULAR' named entity 'INTERFERING' named entity 'ITS' named entity 'TREATMENT' named entity 'OUTSIDE' named entity 'OUTBREAK' named entity 'LIFE CYCLE' named entity 'DEVELOPMENT' named entity 'SURROGATE' named entity 'SCREEN' named entity 'IDENTIFICATION' named entity 'WESTERN AFRICA' named entity 'FAMILY' named entity 'VIRAL ENTRY' named entity 'LARGE' named entity 'IMPACT' named entity 'ONE OF' named entity 'VIRUS-LIKE PARTICLES' named entity 'QUEST' named entity 'CONTAINMENT' named entity 'VIRUSES' named entity 'VIRUS ENTRY' named entity 'DRUG DISCOVERY' named entity 'CHARACTERIZATION' named entity 'DISEASE' named entity 'EBOLA VIRUS' named entity 'CONTEXT' named entity 'ANTIVIRAL' named entity 'VIRAL' named entity 'COMBINATION' named entity 'FILOVIRIDAE' named entity 'THREAT' named entity 'INFECTIONS' named entity 'OUR' named entity 'LETHAL' named entity 'PUBLIC HEALTH' named entity 'MODELS' named entity 'CHARACTERIZED' named entity 'BSL' named entity 'GLOBAL' named entity 'DRUG' named entity 'SCALE' named entity 'EBOLA VIRUS DISEASE' named entity 'SETTING' named entity 'TOOLS' named entity 'POTENTIAL' named entity 'MEMBER OF' named entity 'ACTIVE' named entity 'KNOWLEDGE' named entity 'ANTIVIRALS' named entity 'THEIR' named entity 'GENETIC' named entity 'ALLOWING' named entity 'RECENT' covid:arg/1c7d1097a0fc23516fc084e127333ec4bbf9ca94 named entity 'virus-like particles' named entity 'haploid' named entity 'Ebola virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software